GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (XTER:B8F) » Definitions » ROIC %

Biofrontera AG (XTER:B8F) ROIC % : 31.79% (As of Sep. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Biofrontera AG ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Biofrontera AG's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2023 was 31.79%.

As of today (2024-05-12), Biofrontera AG's WACC % is 2.46%. Biofrontera AG's ROIC % is 3.79% (calculated using TTM income statement data). Biofrontera AG generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


Biofrontera AG ROIC % Historical Data

The historical data trend for Biofrontera AG's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera AG ROIC % Chart

Biofrontera AG Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -87.03 -129.87 -20.37 -61.62 3.52

Biofrontera AG Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.34 -47.88 -17.36 -5.48 31.79

Competitive Comparison of Biofrontera AG's ROIC %

For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera AG's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biofrontera AG's ROIC % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofrontera AG's ROIC % distribution charts can be found below:

* The bar in red indicates where Biofrontera AG's ROIC % falls into.



Biofrontera AG ROIC % Calculation

Biofrontera AG's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROIC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=1.59 * ( 1 - -2.21% )/( (71.105 + 21.162)/ 2 )
=1.625139/46.1335
=3.52 %

where

Biofrontera AG's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2023 is calculated as:

ROIC % (Q: Sep. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Sep. 2023 ))/ count )
=3.768 * ( 1 - -28.47% )/( (15.82 + 14.639)/ 2 )
=4.8407496/15.2295
=31.79 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biofrontera AG  (XTER:B8F) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Biofrontera AG's WACC % is 2.46%. Biofrontera AG's ROIC % is 3.79% (calculated using TTM income statement data). Biofrontera AG generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases. Biofrontera AG earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Biofrontera AG ROIC % Related Terms

Thank you for viewing the detailed overview of Biofrontera AG's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Biofrontera AG (XTER:B8F) Business Description

Traded in Other Exchanges
Address
Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377
Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

Biofrontera AG (XTER:B8F) Headlines

No Headlines